10-Q: Candel Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update

Candel Therapeutics, a clinical-stage biopharmaceutical company, released its third quarter 2024 financial results, highlighting ongoing clinical trials and financial challenges.

Summary

• Candel Therapeutics is a clinical-stage biopharmaceutical company focused on developing viral immunotherapies for cancer treatment.
• The company reported a net loss of $41.1 million for the nine months ended September 30, 2024, and an accumulated deficit of $178.1 million.
• Cash and cash equivalents were $16.6 million as of September 30, 2024.
• The company has raised $7.7 million through an at-the-market offering program as of September 30, 2024, and an additional $2.0 million through November 4, 2024.
• Substantial doubt exists about the company's ability to continue as a going concern for the next year without additional funding.
• The company is advancing clinical trials for CAN-2409 and CAN-3110, with topline data expected in the fourth quarter of 2024 for prostate cancer trials and updated overall survival data for NSCLC and PDAC in the first quarter of 2025.
• The company has received fast track designation for CAN-2409 in NSCLC and PDAC, and for CAN-3110 in recurrent HGG, as well as orphan drug designation for CAN-2409 in pancreatic cancer and CAN-3110 in recurrent HGG.

Sentiment

Score: 4

Explanation: The document presents a mixed picture. While there are positive developments in clinical trials and regulatory designations, the financial situation and going concern warning raise significant concerns, resulting in a negative overall sentiment.

Positives

• The company has received fast track designation for CAN-2409 in NSCLC and PDAC, and for CAN-3110 in recurrent HGG.
• The company has received orphan drug designation for CAN-2409 in pancreatic cancer and CAN-3110 in recurrent HGG.
• The company expects to report topline data for prostate cancer trials in the fourth quarter of 2024.
• Updated overall survival data for CAN-2409 in NSCLC and PDAC is expected in the first quarter of 2025.

Negatives

• The company reported a net loss of $41.1 million for the nine months ended September 30, 2024.
• The company's cash and cash equivalents were $16.6 million as of September 30, 2024.
• Substantial doubt exists about the company's ability to continue as a going concern for the next year without additional funding.
• The company has a term loan with Silicon Valley Bank with a net carrying amount of $14.1 million as of September 30, 2024.

Risks

• The company has a limited operating history and has not generated any revenue from product sales.
• The company expects to continue to incur significant expenses and increasing operating losses for at least the next several years.
• The company's ability to continue as a going concern requires that it obtain sufficient additional funding to finance its operations.
• The company's business is dependent on the success of CAN-2409, CAN-3110 and any other product candidates that it advances into the clinic.
• The company's preclinical studies and clinical trials may fail to demonstrate adequately the safety and efficacy of any of its product candidates.
• The regulatory approval processes of the FDA and comparable foreign regulatory authorities are lengthy, time consuming and inherently unpredictable.
• The company has incurred indebtedness, and may incur additional indebtedness, which could adversely affect its financial condition.
• The company's rights to develop and commercialize certain of its product candidates are subject to the terms and conditions of licenses granted to it by third parties.

Future Outlook

The company expects to continue to generate operating losses and negative cash flows from operations for the foreseeable future and will require additional funding to sustain operations beyond the first quarter of 2025. Topline data from prostate cancer trials is expected in the fourth quarter of 2024, and updated overall survival data for NSCLC and PDAC is expected in the first quarter of 2025.

Management Comments

• Management has determined that substantial doubt exists regarding its ability to continue as a going concern for the one-year period following the date these condensed consolidated financial statements are issued.
• The company expects to finance its cash needs through a combination of public or private equity or debt financings, government grants, and other sources, which may include collaborations, strategic alliances and licensing arrangements with third parties.

Industry Context

The company operates in the competitive biopharmaceutical industry, focusing on novel viral immunotherapies for cancer treatment. The company's progress is being closely watched by investors and competitors alike, as it seeks to bring innovative treatments to market.

Comparison to Industry Standards

• The company's financial position, with a net loss of $41.1 million and cash reserves of $16.6 million, is typical for a clinical-stage biopharmaceutical company.
• The company's reliance on external funding and the going concern warning are common among companies in this sector that are pre-revenue.
• The company's focus on viral immunotherapies places it in a niche market with potential for high growth but also high risk.
• The company's clinical trial progress, including fast track and orphan drug designations, is consistent with industry standards for companies developing novel therapies.
• The company's reliance on third-party manufacturers and CROs is a common practice in the biopharmaceutical industry.

Management Changes

Related Party Transactions

• The company has an exclusive licensing agreement with Ventagen, LLC, an entity owned in part by certain of the company's stockholders.

Stakeholder Impact

• Shareholders face the risk of dilution and potential loss of investment due to the company's need for additional funding.
• Employees may be affected by potential restructuring or changes in operations due to financial constraints.
• Customers (potential patients) may experience delays in the availability of new treatments due to the company's financial challenges.
• Suppliers and creditors may face increased risk due to the company's going concern status.

Next Steps

• The company expects to report topline data for prostate cancer trials in the fourth quarter of 2024.
• The company expects to share updated overall survival data for CAN-2409 in NSCLC and PDAC in the first quarter of 2025.
• The company will continue to seek additional funding to sustain its operations.

Key Dates

Keywords

viral immunotherapy, cancer, CAN-2409, CAN-3110, clinical trials, biopharmaceutical, prostate cancer, NSCLC, pancreatic cancer, recurrent HGG, FDA, orphan drug designation, fast track designation